Aventis Insuman Fourth Quarter NDA Planned After Manufacturing Changes
Executive Summary
Aventis Pharma is targeting a fourth quarter NDA filing for its Insuman recombinant human insulin family after undergoing some changes in the manufacturing process of the compound.